Crestor Shortage: What Providers and Prescribers Need to Know in 2026

Rosuvastatin Availability in 2026: A Provider Briefing

Rosuvastatin (Crestor) remains one of the most widely prescribed medications in the United States, with tens of millions of active prescriptions. While there is no FDA-listed nationwide shortage as of early 2026, clinicians should be aware of supply dynamics that are affecting patient access — and be prepared to counsel patients and adjust treatment plans accordingly.

This briefing covers the current availability picture, what's driving supply disruptions, prescribing implications, and tools to help your patients maintain access to statin therapy.

Timeline of Recent Events

January 2026: Generic Rosuvastatin Recall

In January 2026, approximately 30,000 bottles of generic Rosuvastatin were recalled by a major manufacturer due to out-of-specification dissolution testing results. The affected lots failed to meet dissolution standards, raising concerns about bioavailability and therapeutic equivalence.

While the recall did not affect all manufacturers or all strengths, it created a measurable supply gap — particularly for the 20 mg and 40 mg strengths that account for the majority of prescriptions. The manufacturer has indicated corrective actions are underway, but full recovery of supply may take several months.

Ongoing Supply Chain Factors

Beyond the recall, the generic Rosuvastatin market continues to face pressure from:

• Raw material sourcing constraints — API (active pharmaceutical ingredient) for Rosuvastatin is primarily manufactured overseas
• Thin generic margins — low pricing reduces manufacturer incentive to maintain large buffer inventories
• Distribution consolidation — fewer wholesalers mean less redundancy in the supply chain
• Demand concentration — as one of the top 10 most prescribed drugs in the U.S., even small supply disruptions create significant downstream effects

Prescribing Implications

Dose Equivalency Across Statins

When switching patients from Rosuvastatin to an alternative statin, consider the following approximate equivalencies based on LDL-lowering potency:

• Rosuvastatin 5 mg ≈ Atorvastatin 10 mg ≈ Simvastatin 20 mg ≈ Pravastatin 40 mg
• Rosuvastatin 10 mg ≈ Atorvastatin 20 mg ≈ Simvastatin 40 mg ≈ Pravastatin 80 mg
• Rosuvastatin 20 mg ≈ Atorvastatin 40 mg (Simvastatin 80 mg not recommended due to myopathy risk)
• Rosuvastatin 40 mg ≈ Atorvastatin 80 mg

Note: These are approximate equivalencies. Individual patient response may vary, and lipid panels should be rechecked 6-8 weeks after any switch.

Patient Populations Requiring Extra Attention

Certain patient populations warrant closer monitoring during supply disruptions:

• Post-ACS patients: High-intensity statin therapy is guideline-directed. Any gap in therapy should be minimized.
• Patients with familial hypercholesterolemia: May require specific high-intensity statin therapy and have fewer therapeutic alternatives.
• Patients on complex regimens: Rosuvastatin's favorable drug interaction profile (minimal CYP3A4 metabolism) may have been a deliberate prescribing choice. Switching to Atorvastatin or Simvastatin may introduce interaction concerns, particularly with cyclosporine, HIV protease inhibitors, certain antifungals, and calcium channel blockers.
• Asian patients: Rosuvastatin has specific dosing considerations for Asian patients (recommended starting dose of 5 mg). Equivalent adjustments should be considered when switching.
• Patients with renal impairment: Rosuvastatin dose adjustments are recommended for severe renal impairment (CrCl <30 mL/min). Ensure equivalent adjustments are made for the alternative statin.

Current Availability Picture

The availability landscape for Rosuvastatin in 2026:

• Generic Rosuvastatin tablets — Available but intermittently stocked at some pharmacies. 5 mg and 10 mg strengths are generally easier to find than 20 mg and 40 mg.
• Brand-name Crestor — Available but expensive ($300-$400/month cash price). AstraZeneca's Savings Card can reduce copays for commercially insured patients.
• Ezallor Sprinkle (Rosuvastatin capsules) — An alternative formulation that may have different supply dynamics. Useful for patients with swallowing difficulties.
• Mail-order pharmacies — Generally maintaining more consistent stock than retail pharmacies.

Cost and Access Considerations

Understanding the cost landscape helps you counsel patients effectively:

Generic Rosuvastatin

• Insurance: Typically Tier 1 preferred generic, $0-$15 copay
• Cash with discount cards (GoodRx, SingleCare): $2-$15 for 30 tablets
• Cost Plus Drugs: ~$6.60 for 30 tablets (mail order)
• Walmart $4 program: Available for select strengths

Brand-Name Crestor

• Cash: $300-$400 for 30 tablets
• Insurance: Tier 3 non-preferred brand, $50-$100+ copay
• AstraZeneca Savings Card: Reduces copay for commercially insured patients

Patient Assistance

• AstraZeneca's AZ&Me program: Provides brand Crestor at no cost for qualifying uninsured patients meeting income criteria
• For generic Rosuvastatin, discount cards are typically sufficient to make the medication affordable

For more on helping patients with costs, see our provider's guide to Crestor savings programs.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder helps providers and their staff check real-time pharmacy availability for Rosuvastatin and other medications. Instead of having patients call pharmacy after pharmacy, you can direct them to Medfinder to find stock quickly.

Prescribing Strategies During Supply Disruptions

1. Write for generic Rosuvastatin with "substitution permitted" — allows pharmacists maximum flexibility
2. Specify alternatives on the prescription — include a note like "if Rosuvastatin unavailable, may substitute Atorvastatin [equivalent dose]" (check your state's prescribing rules)
3. Consider 90-day prescriptions — reduces refill frequency and helps patients stock ahead
4. Proactively discuss alternatives with patients who have a history of difficulty filling, so they know what to request if needed
5. Document the clinical rationale for Rosuvastatin if it was chosen for a specific reason (drug interactions, renal dosing, Asian ancestry dosing) to help colleagues and on-call providers make informed decisions

Looking Ahead

The Rosuvastatin supply situation is expected to gradually improve through 2026 as:

• Recall-related manufacturing issues are resolved
• Additional generic manufacturers enter or expand production
• Supply chain redundancy continues to be rebuilt post-pandemic

However, intermittent localized stock-outs are likely to continue. Building awareness of alternatives and patient resources into your clinical workflow will help ensure continuity of care.

Final Thoughts

Rosuvastatin availability in 2026 presents a manageable but real clinical challenge. Proactive prescribing, familiarity with statin dose equivalencies, and awareness of patient access tools like Medfinder will help you keep your patients on appropriate statin therapy during any supply disruptions.

Related resources: How to help your patients find Crestor in stock | Alternatives to Crestor | Crestor drug interactions